Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Modifiable risk factors combined All modifiable factors together | Prevention |
Harm
whyDirection is for carrying the risk factors: the Commission attributes 45% of cases to 14 modifiable factors, which is the same number read the other way as prevention potential. The Commission's own caveat is that "some associations might be only partly causal". |
Population attributable fraction of dementia | systematic review | not stated | "estimated that the PAF for all 14 risk factors was 45.3%" (Table 1: overall PAF 45.3%, rounded 45%); high LDL cholesterol unweighted PAF 18.7%, weighted 6.9%, rounded 7%; untreated vision loss unweighted 6.0%, weighted 2.2%, rounded 2% |
The Lancet
2024 ✓ Peer-reviewed PMID 39096926 |
| Anti-amyloid antibody Medicines | Treatment |
Harm
whyThe review's subject is the harm itself: brain swelling and microbleeds caused by the drugs. |
ARIA incidence and severity | systematic review | not stated | "ARIA-E and ARIA-H occurred in 12.6% and 17.3% of participants on lecanemab, respectively" (CLARITY-AD); "ARIA-E and ARIA-H occurred in 24% and 31% of participants on donanemab, respectively" (TRAILBLAZER-ALZ-2); APOE e4 homozygotes "may have ~2.5 to 5 times greater risk for incident ARIA-E and for ARIA-H" |
Alzheimer's & Dementia
2026 ✓ Peer-reviewed PMID 42015334 |